Antibody-drug conjugate news and latest updates

Podcast 11 Oct 2024

Bispecific ADCs: the next generation of cancer treatments

To talk about bispecific ADCs, and biotechs in Czechia, our conversation this week is with Radek Špíšek, CEO of SOTIO.

October 11, 2024

ADCs that deliver: The secret lies in rigorous characterization

Explore the challenges of ADC characterization, key techniques, and the benefits of partnering with a CDMO for effective development.

September 17, 2024 - 7 minutesmins - By Ute Boronowsky

News and Trends 4 Sep 2024

2024: a year of breakthroughs for endometrial cancer?

New treatments have been approved by regulators for endometrial cancer, which are regarded as major therapeutic breakthroughs.

September 4, 2024 - 7 minutesmins - By Roohi Mariam Peter

Podcast 21 Jun 2024

How ADCs can deliver death cap mushroom toxins to treat cancer

Listen to our conversation with Heidelberg Pharma about its lead amanitin-based ADC product candidate, HDP-101.

June 21, 2024

Best in Biotech 8 Feb 2024

Fourteen biotech companies spearheading the antibody drug conjugate industry

The antibody-drug conjugate market has gained significant traction recently. Discover some of the top ADC companies in the industry.

February 8, 2024 - 18 minutesmins - By Jules Adam

News and Trends 20 Nov 2023

M&As: what’s up with the ADC buying spree?

Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]

November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter

In Depth 13 Oct 2023

How close are we to a cure for metastatic breast cancer?

Currently considered an incurable disease, there is a lot of work being done around developing better treatment options for metastatic breast cancer, and, ultimately, a cure. Numerous promising candidates are in clinical trials, all with the hope of progressing toward U.S. Food and Drug Administration (FDA) approval. According to the World Health Organization (WHO), 2.3 […]

October 13, 2023 - 8 minutesmins - By Willow Shah-Neville

News and Trends 27 Jul 2023

Epsilogen completes first clinical trial of IgE antibody to treat cancer

Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target […]

July 27, 2023 - 2 minutesmins - By Jim Cornall

In Depth 26 Jul 2023

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine

The first-ever antibody-drug conjugate (ADC) to be approved, gemtuzumab ozogamicin, raised hope for a new class of drugs to treat cancer. But the drug was then withdrawn following a black box warning after patients experienced adverse side effects, and there had been fatalities. But this didn’t discourage biopharmas looking to create safer alternatives from expediting […]

July 26, 2023 - 7 minutesmins - By Roohi Mariam Peter

Podcast 7 Jul 2023

Beyond Biotech podcast 53: Antibody-drug conjugates

On the podcast this week, we have a conversation about antibody-drug conjugates with Pejvack Motlagh, who was recently announced as the chief medical officer at Mablink Bioscience. Mablink Bioscience Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs, antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLink, […]

July 7, 2023

News and Trends 1 Jun 2023

Lonza boosts ADC portfolio with Synaffix acquisition

Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs). While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platform, which […]

June 1, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

ADC firm Adcentrx Therapeutics aims for clinic after $38M boost

Antibody-drug conjugate (ADC) biotech company Adcentrx Therapeutics has closed a $38 million Series A+ financing. The round was led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, Trinity Innovation Fund, and other strategic investors. Life Venture Partners and Lighthouse Capital acted as Adcentrx’s financial advisors. Adcentrx Therapeutics intends to use the […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us